MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-10-2023
Syneos Health Total Assets 2011-2026 | SYNH
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Syneos Health
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 8.24 B | 8.06 B | 7.45 B | 7.25 B | 7.29 B | 1.29 B | 1.21 B | 1.25 B | 1.23 B | 1.26 B | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.24 B | 1.21 B | 4.45 B |
Quarterly Total Assets Syneos Health
| 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.1 B | 8.2 B | - | - | 8.3 B | 8.24 B | 8.22 B | 8.02 B | 7.95 B | 8.06 B | 8.06 B | 8.06 B | 8.06 B | 7.45 B | 7.45 B | 7.45 B | 7.45 B | 7.25 B | 7.25 B | 7.25 B | 7.25 B | 7.29 B | 7.29 B | 7.29 B | 7.29 B | 1.29 B | 1.29 B | 1.29 B | 1.29 B | 1.21 B | 1.21 B | 1.21 B | 1.21 B | 1.24 B | 1.25 B | 1.25 B | 1.25 B | 1.23 B | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.3 B | 1.21 B | 5.37 B |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
10.7 B | $ 116.92 | 2.67 % | $ 35.5 B |  USA |
 |
Aspira Women's Health
AWH
|
5.46 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
73.6 M | $ 1.18 | 0.85 % | $ 6.43 M | USA |
 |
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | USA |
 |
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
413 M | $ 17.92 | 1.41 % | $ 955 M | USA |
 |
Exact Sciences Corporation
EXAS
|
5.86 B | - | - | $ 19.8 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M |  Britain |
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Burning Rock Biotech Limited
BNR
|
2.28 B | $ 16.24 | 0.93 % | $ 175 M |  China |
 |
Co-Diagnostics
CODX
|
24.7 M | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Interpace Biosciences
IDXG
|
33.8 M | $ 1.98 | -0.63 % | $ 8.76 M | USA |
 |
Illumina
ILMN
|
6.3 B | $ 128.0 | 1.23 % | $ 20.4 B | USA |
 |
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M | USA |
 |
Castle Biosciences
CSTL
|
531 M | $ 25.19 | 1.45 % | $ 700 M | USA |
 |
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | China |
 |
Laboratory Corporation of America Holdings
LH
|
18.4 B | $ 274.72 | 2.06 % | $ 22.9 B | USA |
 |
Charles River Laboratories International
CRL
|
7.14 B | $ 175.07 | 3.26 % | $ 8.68 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | USA |
 |
Medpace Holdings
MEDP
|
1.98 B | $ 520.65 | 2.39 % | $ 15 B | USA |
 |
Danaher Corporation
DHR
|
83.5 B | $ 196.19 | 2.71 % | $ 140 B | USA |
 |
Motus GI Holdings
MOTS
|
7.22 M | - | -34.28 % | $ 263 K |  Israel |
 |
Myriad Genetics
MYGN
|
707 M | $ 4.77 | 0.63 % | $ 442 M | USA |
 |
Neogen Corporation
NEOG
|
3.44 B | $ 10.34 | 3.61 % | $ 2.24 B | USA |
 |
National Research Corporation
NRC
|
135 M | $ 17.26 | 1.29 % | $ 386 M | USA |
 |
Natera
NTRA
|
1.39 B | $ 210.83 | 0.75 % | $ 20.7 B | USA |
 |
Invitae Corporation
NVTA
|
1.95 B | - | - | $ 21.2 M | USA |
 |
Organovo Holdings
ONVO
|
14.6 M | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
9.86 M | - | -16.95 % | $ 1.54 M | USA |
 |
Fulgent Genetics
FLGT
|
1.22 B | $ 15.83 | -0.5 % | $ 479 M | USA |
 |
Pacific Biosciences of California
PACB
|
784 M | $ 1.47 | 2.08 % | $ 441 M | USA |
 |
Guardant Health
GH
|
2.01 B | $ 92.84 | -0.49 % | $ 11.6 B | USA |
 |
PerkinElmer
PKI
|
12.2 B | - | -0.91 % | $ 14.7 B | USA |
 |
QIAGEN N.V.
QGEN
|
6.28 B | - | - | $ 10.6 B |  Niderland |
 |
Psychemedics Corporation
PMD
|
12.3 M | - | -1.84 % | $ 15.3 M | USA |
 |
Personalis
PSNL
|
270 M | $ 6.33 | 2.59 % | $ 375 M | USA |
 |
Anixa Biosciences
ANIX
|
16.1 M | $ 2.73 | 1.49 % | $ 88.6 K | USA |
 |
Biomerica
BMRA
|
5.94 M | $ 2.15 | -0.46 % | $ 4.94 M | USA |
 |
Quotient Limited
QTNT
|
220 M | - | -11.32 % | $ 1.1 M |  Schweiz |
 |
ICON Public Limited Company
ICLR
|
16.9 B | $ 106.54 | -0.58 % | $ 8.79 B |  Irlanda |
 |
Check-Cap Ltd.
CHEK
|
377 K | - | - | $ 9.42 M | Israel |
 |
Celcuity
CELC
|
467 M | $ 116.94 | 1.19 % | $ 5.47 B | USA |